Rexahn Pharmaceuticals has completed patient enrollment in its Phase II clinical trial designed to investigate the ability of Archexinin to treat metastatic pancreatic cancer.
Archexin, an Akt protein kinase inhibitor, inhibits cancer cell survival and proliferation, angiogenesis and drug resistance.
Phase I clinical trial data has shown that Archexin has a human safety profile, with fatigue being the only side effect.
The two-stage, single arm, open label study in combination with gemcitabine enrolled approximately 35 patients to evaluate the overall survival rate of the patients treated with the drug candidate.
Rexahn president and chief operating officer Rick Soni said they expect to report preliminary results in the first half of 2012.
Archexin has obtained FDA orphan drug designation to treat renal cell carcinoma, glioblastoma, pancreatic, stomach and ovarian cancers.
